188 related articles for article (PubMed ID: 25124362)
1. Glucose-lowering effect of insulin degludec is independent of subcutaneous injection region.
Nosek L; Coester HV; Roepstorff C; Thomsen HF; Kristensen NR; Haahr H; Heise T
Clin Drug Investig; 2014 Sep; 34(9):673-9. PubMed ID: 25124362
[TBL] [Abstract][Full Text] [Related]
2. Ultra-long pharmacokinetic properties of insulin degludec are comparable in elderly subjects and younger adults with type 1 diabetes mellitus.
Korsatko S; Deller S; Mader JK; Glettler K; Koehler G; Treiber G; Urschitz M; Wolf M; Hastrup H; Søndergaard F; Haahr H; Pieber TR
Drugs Aging; 2014 Jan; 31(1):47-53. PubMed ID: 24263619
[TBL] [Abstract][Full Text] [Related]
3. Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes.
Heise T; Nosek L; Bøttcher SG; Hastrup H; Haahr H
Diabetes Obes Metab; 2012 Oct; 14(10):944-50. PubMed ID: 22726241
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine.
Heise T; Hövelmann U; Nosek L; Hermanski L; Bøttcher SG; Haahr H
Expert Opin Drug Metab Toxicol; 2015; 11(8):1193-201. PubMed ID: 26086190
[TBL] [Abstract][Full Text] [Related]
5. A comparison of the steady-state pharmacokinetic and pharmacodynamic profiles of 100 and 200 U/mL formulations of ultra-long-acting insulin degludec.
Korsatko S; Deller S; Koehler G; Mader JK; Neubauer K; Adrian CL; Thomsen H; Haahr H; Pieber TR
Clin Drug Investig; 2013 Jul; 33(7):515-21. PubMed ID: 23749405
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic and pharmacodynamic responses of insulin degludec in African American, white, and Hispanic/Latino patients with type 2 diabetes mellitus.
Hompesch M; Morrow L; Watkins E; Roepstorff C; Thomsen HF; Haahr H
Clin Ther; 2014 Apr; 36(4):507-15. PubMed ID: 24508419
[TBL] [Abstract][Full Text] [Related]
7. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes.
Heise T; Hermanski L; Nosek L; Feldman A; Rasmussen S; Haahr H
Diabetes Obes Metab; 2012 Sep; 14(9):859-64. PubMed ID: 22594461
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic and pharmacodynamic properties of insulin degludec in Japanese patients with type 1 diabetes mellitus reflect similarities with Caucasian patients.
Ikushima I; Kaku K; Hirao K; Bardtrum L; Haahr H
J Diabetes Investig; 2016 Mar; 7(2):270-5. PubMed ID: 27042281
[TBL] [Abstract][Full Text] [Related]
9. Insulin degludec/insulin aspart produces a dose-proportional glucose-lowering effect in subjects with type 1 diabetes mellitus.
Heise T; Nosek L; Klein O; Coester H; Svendsen AL; Haahr H
Diabetes Obes Metab; 2015 Jul; 17(7):659-64. PubMed ID: 25772444
[TBL] [Abstract][Full Text] [Related]
10. Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects.
Mudaliar SR; Lindberg FA; Joyce M; Beerdsen P; Strange P; Lin A; Henry RR
Diabetes Care; 1999 Sep; 22(9):1501-6. PubMed ID: 10480516
[TBL] [Abstract][Full Text] [Related]
11. The Distinct Prandial and Basal Pharmacodynamics of IDegAsp Observed in Younger Adults Are Preserved in Elderly Subjects with Type 1 Diabetes.
Brunner M; Pieber T; Korsatko S; Kojzar H; Svendsen AL; Haahr H
Drugs Aging; 2015 Jul; 32(7):583-90. PubMed ID: 26088815
[TBL] [Abstract][Full Text] [Related]
12. Steady state is reached within 2-3 days of once-daily administration of degludec, a basal insulin with an ultralong duration of action.
Heise T; Korsatko S; Nosek L; Coester HV; Deller S; Roepstorff C; Segel S; Kapur R; Haahr H; Hompesch M
J Diabetes; 2016 Jan; 8(1):132-8. PubMed ID: 25581159
[TBL] [Abstract][Full Text] [Related]
13. Insulin degludec/insulin aspart in Japanese patients with type 1 diabetes mellitus: Distinct prandial and basal glucose-lowering effects.
Haahr H; Sasaki T; Bardtrum L; Ikushima I
J Diabetes Investig; 2016 Jul; 7(4):574-80. PubMed ID: 27181070
[TBL] [Abstract][Full Text] [Related]
14. Insulin degludec's ultra-long pharmacokinetic properties observed in adults are retained in children and adolescents with type 1 diabetes.
Biester T; Blaesig S; Remus K; Aschemeier B; Kordonouri O; Granhall C; Søndergaard F; Kristensen NR; Haahr H; Danne T
Pediatr Diabetes; 2014 Feb; 15(1):27-33. PubMed ID: 24467565
[TBL] [Abstract][Full Text] [Related]
15. Comparison of pharmacokinetic and pharmacodynamic properties of single-dose oral insulin spray and subcutaneous insulin injection in healthy subjects using the euglycemic clamp technique.
Cernea S; Kidron M; Wohlgelernter J; Modi P; Raz I
Clin Ther; 2004 Dec; 26(12):2084-91. PubMed ID: 15823772
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic and Pharmacodynamic Characteristics of Insulin Icodec After Subcutaneous Administration in the Thigh, Abdomen or Upper Arm in Individuals with Type 2 Diabetes Mellitus.
Plum-Mörschel L; Andersen LR; Hansen S; Hövelmann U; Krawietz P; Kristensen NR; Lehrskov LL; Haahr H
Clin Drug Investig; 2023 Feb; 43(2):119-127. PubMed ID: 36631720
[TBL] [Abstract][Full Text] [Related]
17. A phase-I randomized euglycemic clamp study to demonstrate the pharmacokinetic and pharmacodynamic equivalence of an insulin degludec biosimilar (B01411) with the reference product in healthy Chinese volunteers.
Liu H; Li T; Yu H; Chen X; Li J; Tan H; Jia D; Yu Y
Expert Opin Investig Drugs; 2023; 32(8):773-781. PubMed ID: 37665683
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic and prandial pharmacodynamic properties of insulin degludec/insulin aspart in children, adolescents, and adults with type 1 diabetes.
Biester T; Danne T; Bläsig S; Remus K; Aschemeier B; Kordonouri O; Bardtrum L; Haahr H
Pediatr Diabetes; 2016 Dec; 17(8):642-649. PubMed ID: 26782928
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamics of the long-acting insulin analogues detemir and glargine following single-doses and under steady-state conditions in patients with type 1 diabetes.
Koehler G; Treiber G; Wutte A; Korsatko S; Mader JK; Semlitsch B; Pieber TR
Diabetes Obes Metab; 2014 Jan; 16(1):57-62. PubMed ID: 23841569
[TBL] [Abstract][Full Text] [Related]
20. A review of the pharmacological properties of insulin degludec and their clinical relevance.
Haahr H; Heise T
Clin Pharmacokinet; 2014 Sep; 53(9):787-800. PubMed ID: 25179915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
